 |
| Nick Timmins PhD |
In the final session
of day two at Cell Therapy Therapy Bioprocessing
& Commercialization, Nick Timmins PhD, director of product
and process development at the Centre for Commercialization of Regenerative
Medicine, told attendees that the key bottlenecks and technology
gaps in bioprocessing and commercialization of cell therapies are
centered around equipment and resources.
He said that while each had different reasons for occurring and different
solutions, each delay and prohibit your outcome. “The ideal pathway would be
two parallel lines that increase in profits and production,” he said.
Timmins referred to three
main issues in technology that often present themselves; connectivity,
automation, and data capture & use. “These major gaps in the process are
difficult to implement a solution for and require detailed thought out
execution,” he said.
As he continued to explain
different scenarios and cases of how bottlenecks and technology gaps have
prohibited growth, Timmins concluded his talk with two major takeaways:
One; think beyond a single
batch – industrialization, plant and equipment utilization, and theory of
constraints.
And two; discriminate
between bottlenecks and technology gaps – they are different things with
different answers, they also have a different cost vs benefit analysis that
needs to be taken into account.
Join the conversation on Twitter by following #IBC_CTB15
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment